All News
The RheumNow podcast on #ACR20 Day 1 Part II is now available for download. Follow the link below to listen in or find us on Apple.
https://t.co/W6EMQiF9Rf https://t.co/ZlFDiVgAKl
Links:
Dr. John Cush RheumNow ( View Tweet)
Withdrawal of MMF may be safely in #SLE patients in remission #ACR20 @RheumNow Dr Chakravarty https://t.co/xnpagKNu96
Sole RetamozoSole ( View Tweet)
Dr Joan Merrill presents a phase 2 trial
use of Iberdomide in patients with #SLE
-Novel MOA —> blocks TF Ailos and Ikaros
Conclusion
-Primary end point was met at week 24
-Effects greater in Aiolos high/Type 2 IFN high
-Iverdomdie was tolerated well
#Lupus
#ACR20
#ACRambassador https://t.co/zpQR9ceV7p
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
When you counsel patients w/RA, do you warn them that during times of dz flare, their ability to drive may be affected? ...maybe you should based on Abstr#0198
#ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j
Olga Petryna DrPetryna ( View Tweet)
I admit I don’t get it. Warfarin has more cartilage loss than DOACs. Is this real or a reflection of diff access to cheap vs expensive meds?Duration response seen. Need RCT or subanalysis of a fib RCTs. #bestinclass great trainee plenary #934 @RheumNow @CRASCRRheum #ACR20 https://t.co/Eg1ymtDdmI
Janet Pope Janetbirdope ( View Tweet)
It's only now we have choices to warfarin that we can realise the effect of vit K blockade on OA.
Nested case-control (AF pts, UK primary care):
warfarin has risk vs DOAC for end-stage OA (via joint replacement) aOR 1.25
esp knee aOR 1.48
@Tuhina_Neogi #ACR20 ABST0934 @RheumNow https://t.co/XVLG8kIL0W
David Liew drdavidliew ( View Tweet)
Plenary session: Dr Ballal presents data showing #warfarin use incr. risk of knee/hip replacements, compared to #DOACs
- Nest case-control study in UK THIN database
- Risk increases w/ duration of use
- Indicates need for well-powered RCT of vit K in OA
Abs#0934 #ACR20 @RheumNow https://t.co/YyxDjNQEjx
Mrinalini Dey DrMiniDey ( View Tweet)
50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe
Janet Pope Janetbirdope ( View Tweet)
ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s
Janet Pope Janetbirdope ( View Tweet)
Great talk by @lovetolearn27 Prosthetic joint infection doubles the risk of venous thromboembolism after revision of knee replacement. 15 yr data New York state -25K revisions! @RheumNow #ACR20 ABS#0960 https://t.co/4PHHSEstKs
Bella Mehta bella_mehta ( View Tweet)
Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk
Eric Dein ejdein1 ( View Tweet)
Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP
Janet Pope Janetbirdope ( View Tweet)
Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs
Janet Pope Janetbirdope ( View Tweet)
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB
Richard Conway RichardPAConway ( View Tweet)
Study of 372 new #hydroxychloroquine users suggests risk of #HCQ #retinopathy at 10yrs is lower compared to previous prevalence-based estimates, although dose >5mg/kg may increase this risk.
#RheumTwitter Abs#0540 #ACR20 @RheumNow
https://t.co/kOSToCljeq
Mrinalini Dey DrMiniDey ( View Tweet)
Mayo study found incidence of HCQ retinopathy w/ <5 mg/kg/d 5 years = 0%, at 10 years = 2.5%
(historically w/ 6.5 mg/kg/d 5 yr incidence 1%,10 years 2%, 20 years 20%)
Based on this study, which dose of HCQ will you prescribe?
Abstr#540 #ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
sheila RHEUMarampa ( View Tweet)
Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
David Liew drdavidliew ( View Tweet)
Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed
Session Date Monday, November 9
Presentation Time: 12:15 PM - 12:30 PM ET
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
